The BIOSECURE Act was passed with a large bipartisan majority in the House in 2024 and now awaits action in the Senate in 2025. Passage of the Act would be a significant first step in protecting ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation created a window of reprieve for the affected biotech companies.

Pharma Sector Multibagger Opportunity - Explore how India could win big in the CDMO space with China-Plus-One strategy, ...

$510,000 of ACADIA PHARMACEUTICALS lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Implementation of the Inflation ...

It is now apparent that nearly every Trump appointee is a diehard anti-China high priest or priestess. That’s not just Marco ...

Indian pharma companies like Dr Reddys, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term.

The proposed Biosecure Act as well as the diversification of American and European firms away from China are expected to help contract drug makers in India India's drugmakers ramped up C-suite ...

Like many industries preparing for Donald Trump's second term as president, the prospects for the healthcare industry are a ...

The US House of Representatives passed the Biosecure Act in September, which would ban federal contracts with targeted firms and their business partners. The legislation, which explicitly names ...